De Lisle Partners LLP Roivant Sciences Ltd. Transaction History
De Lisle Partners LLP
- $682 Billion
- Q4 2024
A detailed history of De Lisle Partners LLP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, De Lisle Partners LLP holds 50,000 shares of ROIV stock, worth $542,500. This represents 0.09% of its overall portfolio holdings.
Number of Shares
50,000
Previous 90,000
44.44%
Holding current value
$542,500
Previous $1.04 Billion
43.0%
% of portfolio
0.09%
Previous 0.17%
Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$714 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$673 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$519 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$478 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$384 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.64B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...